1831 related items for PubMed ID: 17288696
1. Resource utilization in asthma: combined fluticasone propionate/salmeterol compared with inhaled corticosteroids.
Friedman HS, Yawn BP.
Curr Med Res Opin; 2007 Feb; 23(2):427-34. PubMed ID: 17288696
[Abstract] [Full Text] [Related]
2. Effects of fluticasone propionate/salmeterol combination on asthma-related health care resource utilization and costs and adherence in children and adults with asthma.
Delea TE, Hagiwara M, Stanford RH, Stempel DA.
Clin Ther; 2008 Mar; 30(3):560-71. PubMed ID: 18405796
[Abstract] [Full Text] [Related]
3. Retrospective claims study of fluticasone propionate/salmeterol fixed-dose combination use as initial asthma controller therapy in children despite guideline recommendations.
Friedman HS, Eid NS, Crespi S, Wilcox TK, Reardon G.
Clin Ther; 2009 May; 31(5):1056-63. PubMed ID: 19539106
[Abstract] [Full Text] [Related]
4. Resource utilization with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies in children with asthma.
Stempel DA, Riedel AA, Carranza Rosenzweig JR.
Curr Med Res Opin; 2006 Mar; 22(3):463-70. PubMed ID: 16574030
[Abstract] [Full Text] [Related]
5. Effect of fluticasone propionate and salmeterol in a single device, fluticasone propionate, and montelukast on overall asthma control, exacerbations, and costs.
O'Connor RD, Stanford R, Crim C, Yancey SW, Edwards L, Rickard KA, Dorinsky P.
Ann Allergy Asthma Immunol; 2004 Dec; 93(6):581-8. PubMed ID: 15609769
[Abstract] [Full Text] [Related]
6. Mometasone furoate vs fluticasone propionate with salmeterol: multivariate analysis of resource use and asthma-related charges.
Navaratnam P, Friedman HS, Urdaneta E.
Curr Med Res Opin; 2009 Dec; 25(12):2895-901. PubMed ID: 19821655
[Abstract] [Full Text] [Related]
7. Costs and resource use of mild persistent asthma patients initiated on controller therapy.
Colice GL, Yu AP, Ivanova JI, Hsieh M, Birnbaum HG, Lage MJ, Brewster C.
J Asthma; 2008 May; 45(4):293-9. PubMed ID: 18446593
[Abstract] [Full Text] [Related]
8. Risk of asthma exacerbation, asthma-related health care utilization and costs, and adherence to controller therapy in patients with asthma receiving fluticasone propionate/salmeterol inhalation powder 100 μg/50 μg versus mometasone furoate inhalation powder.
Hagiwara M, Delea TE, Stanford RH.
J Asthma; 2013 Apr; 50(3):287-95. PubMed ID: 23305687
[Abstract] [Full Text] [Related]
9. Does measuring BHR add to guideline derived clinical measures in determining treatment for patients with persistent asthma?
Koenig SM, Murray JJ, Wolfe J, Andersen L, Yancey S, Prillaman B, Stauffer J, Dorinsky P.
Respir Med; 2008 May; 102(5):665-73. PubMed ID: 18328683
[Abstract] [Full Text] [Related]
10. Appropriate use of inhaled corticosteroid and long-acting beta(2)-adrenergic agonist combination therapy among asthma patients in a US commercially insured population.
Ye X, Gutierrez B, Zarotsky V, Nelson M, Blanchette CM.
Curr Med Res Opin; 2009 Sep; 25(9):2251-8. PubMed ID: 19622006
[Abstract] [Full Text] [Related]
11. Association between previous health care use and initiation of inhaled corticosteroid and long-acting beta2-adrenergic agonist combination therapy among US patients with asthma.
Blanchette CM, Culler SD, Ershoff D, Gutierrez B.
Clin Ther; 2009 Nov; 31(11):2574-83. PubMed ID: 20110003
[Abstract] [Full Text] [Related]
12. Effect of combination fluticasone propionate and salmeterol or inhaled corticosteroids on asthma-related outcomes in a Medicare-eligible population.
Stanford RH, Blanchette CM, Roberts MH, Petersen H, Fuhlbrigge AL.
Am J Geriatr Pharmacother; 2012 Dec; 10(6):343-51. PubMed ID: 23083688
[Abstract] [Full Text] [Related]
13. Inhaled corticosteroids vs leukotriene receptor antagonists: health care costs across varying asthma severities.
O'Connor RD, Parasuraman B, Roberts C, Leibman C.
Ann Allergy Asthma Immunol; 2006 Aug; 97(2):236-43. PubMed ID: 16937758
[Abstract] [Full Text] [Related]
14. Comparison of prevalence, cost, and outcomes of a combination of salmeterol and fluticasone therapy to common asthma treatments.
Wang SW, Liu X, Wiener DJ, Sennett C, Bowers BW, Legorreta AP.
Am J Manag Care; 2001 Sep; 7(9):913-22. PubMed ID: 11570024
[Abstract] [Full Text] [Related]
15. Asthma hospitalization risk and costs for patients treated with fluticasone propionate vs montelukast.
Orsini L, Limpa-Amara S, Crown WH, Stanford RH, Kamal K.
Ann Allergy Asthma Immunol; 2004 May; 92(5):523-9. PubMed ID: 15191020
[Abstract] [Full Text] [Related]
16. Outcomes and costs of patients with persistent asthma treated with beclomethasone dipropionate hydrofluoroalkane or fluticasone propionate.
Lage MJ, Gross GN, Brewster C, Spalitto A.
Adv Ther; 2009 Aug; 26(8):762-75. PubMed ID: 19669630
[Abstract] [Full Text] [Related]
17. Moderate dose inhaled corticosteroids plus salmeterol versus higher doses of inhaled corticosteroids in symptomatic asthma.
Masoli M, Weatherall M, Holt S, Beasley R.
Thorax; 2005 Sep; 60(9):730-4. PubMed ID: 16135679
[Abstract] [Full Text] [Related]
18. Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies.
Stoloff SW, Stempel DA, Meyer J, Stanford RH, Carranza Rosenzweig JR.
J Allergy Clin Immunol; 2004 Feb; 113(2):245-51. PubMed ID: 14767437
[Abstract] [Full Text] [Related]
19. Retrospective comparison of early versus late treatment with fluticasone propionate/salmeterol after an asthma exacerbation.
Hagiwara M, Delea TE, Stanford RH.
J Asthma; 2011 Sep; 48(7):721-8. PubMed ID: 21793768
[Abstract] [Full Text] [Related]
20. Comparison of hospitalizations, emergency department visits, and costs in a historical cohort of Texas Medicaid patients with chronic obstructive pulmonary disease, by initial medication regimen.
Rascati KL, Akazawa M, Johnsrud M, Stanford RH, Blanchette CM.
Clin Ther; 2007 Jun; 29(6):1203-13. PubMed ID: 17692734
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
